Literature DB >> 19996200

Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.

Varsha Gandhi1, Jan A Burger.   

Abstract

Entities:  

Year:  2009        PMID： 19996200      PMCID： PMC2795094          DOI： 10.1158/1078-0432.CCR-08-3041

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  35 in total

1.  Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

Authors:  T Lissitchkov; G Arnaudov; D Peytchev; Kh Merkle
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

Review 3.  [Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride].

Authors:  G Anger; P Hesse; H Baufeld
Journal:  Dtsch Med Wochenschr       Date:  1969-11-28       Impact factor: 0.628

4.  Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride.

Authors:  Jens Teichert; Frank Baumann; Qi Chao; Craig Franklin; Brandy Bailey; Lothar Hennig; Karel Caca; Konrad Schoppmeyer; Ulrich Patzak; Rainer Preiss
Journal:  Cancer Chemother Pharmacol       Date:  2006-09-07       Impact factor: 3.333

5.  Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

Authors:  D Strumberg; A Harstrick; K Doll; B Hoffmann; S Seeber
Journal:  Anticancer Drugs       Date:  1996-06       Impact factor: 2.248

6.  [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice].

Authors:  H Weber; R Amlacher; R Preiss; H Hoffmann
Journal:  Pharmazie       Date:  1991-08       Impact factor: 1.267

7.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Authors:  K Sue Robinson; Michael E Williams; Richard H van der Jagt; Philip Cohen; Jordan A Herst; Anil Tulpule; Lee S Schwartzberg; Bernard Lemieux; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

8.  [On the methodology of the determination of alkylating activities of nitrogen mustards with nitrobenzylpyridine (NBP) in biological material (author's transl)].

Authors:  G Hesse; W Schulze; E Wachtel
Journal:  Pharmazie       Date:  1981-09       Impact factor: 1.267

9.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Authors:  Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
View more
  12 in total

1.  DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.

Authors:  Scott R Goldsmith; Mark A Fiala; Brandon Wang; Mark A Schroeder; Tanya M Wildes; Armin Ghobadi; Keith Stockerl-Goldstein; Ravi Vij
Journal:  Ann Hematol       Date:  2020-03-04       Impact factor: 3.673

2.  Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Authors:  Fabiola Cervantes-Gomez; Betty Lamothe; Jennifer A Woyach; William G Wierda; Michael J Keating; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 3.  Update on therapy of chronic lymphocytic leukemia.

Authors:  John G Gribben; Susan O'Brien
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma.

Authors:  Issa Ismail Issa; Rasmus Froberg Brøndum; Hanne Due; Linnéa Schmidt; Martin Bøgsted; Karen Dybkær
Journal:  Cancer Drug Resist       Date:  2021-03-19

5.  Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.

Authors:  Qingshan Yang; Lisa S Chen; Sattva S Neelapu; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

6.  Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Authors:  Amal A El-Mabhouh; Mary L Ayres; Elizabeth J Shpall; Veerabhadran Baladandayuthapani; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

7.  Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.

Authors:  Prexy Modi; Kumudha Balakrishnan; Qingshan Yang; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Oncotarget       Date:  2017-03-07

Review 8.  Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).

Authors:  Hrvoje Lalic; Igor Aurer; Drago Batinic; Dora Visnjic; Tomislav Smoljo; Antonija Babic
Journal:  Oncol Rep       Date:  2022-05-04       Impact factor: 4.136

9.  Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death.

Authors:  Megan S Molina; Emely A Hoffman; Jessica Stokes; Nicole Kummet; Kyle A Smith; Forrest Baker; Tiffany M Zúñiga; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

10.  A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

Authors:  Nitin Jain; Kumudha Balakrishnan; Alessandra Ferrajoli; Susan M O'Brien; Jan A Burger; Tapan M Kadia; Jorge E Cortes; Mary L Ayres; Francesco Paolo Tambaro; Michael J Keating; Varsha Gandhi; William G Wierda
Journal:  Oncotarget       Date:  2017-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.